How BioSig's PURE EP Beats The Competition

TM editors' note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.

The April 2017 issue of the Journal of Innovations in Cardiac Rhythm Management has an excellent paper on why BioSig's PURE EP™ is a superior electrophysiology signal recording and processing system to existing systems and positioned to shake-up the entire EP market when launched in 2018. The paper was published by a team of cardiologists and electrophysiologists at Mayo Clinic, Harvard Medical School, and BioSig Technologies, Inc. (BSGM).

The paper is titled, "Initial Experience with the BioSig PURE EP Signal Recording System: An Animal Laboratory Experience" and is rather technical. Investors wishing to read the paper can simply click on JI-CRM logo and it will pop open the PDF. Below is my summary of the key findings by the team of physicians and what this means for investors in BioSig Technologies.

A Quick Backgrounder

An electrophysiology study (EPS) is a diagnostic procedure performed by a specialized cardiologist, called an electrophysiologist, with the intent to help understand the nature of an abnormal heart rhythm. An arrhythmia is an abnormal heartbeat or a change from the normal sequence of electrical impulses that control the beating (contraction) of the heart. Atrial fibrillation (AF) is the most common form of arrhythmia and affects an estimated 2.7 million Americans.

1 2 3
View single page >> |

Disclosure:Please see important information about BioNap and our financial relationship with companies mentioned above our  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.